Literature DB >> 26296835

Risk of New-Onset Dyslipidemia After Laparoscopic Adrenalectomy in Patients with Primary Aldosteronism.

Mayuko Kaga1, Takanobu Utsumi2, Tomoaki Tanaka3, Takashi Kono3, Hidekazu Nagano3, Koji Kawamura1, Naoto Kamiya4, Takashi Imamoto1, Naoki Nihei1, Yukio Naya5, Hiroyoshi Suzuki4, Tomohiko Ichikawa1.   

Abstract

BACKGROUND: Many patients with primary aldosteronism (PA) show a significant decline in kidney function after adrenalectomy. Thus, PA patients who undergo surgery are at greater risk of both postoperative renal damage and new-onset metabolic events associated with renal insufficiency. The aim of this study was to explore postoperative changes in serum lipid levels and to identify risk factors associated with postoperative new-onset dyslipidemia in PA patients.
METHODS: The records of 57 Japanese patients who underwent unilateral laparoscopic adrenalectomy for PA were retrospectively surveyed. Clinical and biochemical data were evaluated at baseline and 12 months after surgery. Preoperative and postoperative estimated glomerular filtration (eGFR) and serum lipid profile, including triglycerides, high-density lipoprotein (HDL)-cholesterol and low-density lipoprotein (LDL)-cholesterol levels, were compared. Furthermore, uni- and multivariate analyses were performed to determine the predictors for postoperative new-onset dyslipidemia.
RESULTS: A significant decrease in eGFR and deterioration of serum lipid levels was identified postoperatively in most patients. Of the 39 patients without pre-existing dyslipidemia, 18 developed new-onset dyslipidemia postoperatively. Multivariate analysis identified preoperative lower eGFR and higher body mass index as independent predictors for new-onset dyslipidemia after surgery. On univariate analyses, additional factors associated with new-onset dyslipidemia included older age, male sex, higher LDL-cholesterol, and higher LDL/HDL ratio.
CONCLUSIONS: PA patients had a higher risk of postoperative new-onset or progressive dyslipidemia. Clinicians should pay attention to not only follow-up of renal impairment but also total management of new-onset metabolic events associated with renal insufficiency in PA patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26296835     DOI: 10.1007/s00268-015-3197-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

1.  High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma.

Authors:  Takanobu Utsumi; Koji Kawamura; Takashi Imamoto; Naoto Kamiya; Akira Komiya; Sawako Suzuki; Hidekazu Nagano; Tomoaki Tanaka; Naoki Nihei; Yukio Naya; Hiroyoshi Suzuki; Ichiro Tatsuno; Tomohiko Ichikawa
Journal:  Surgery       Date:  2011-10-13       Impact factor: 3.982

2.  Impact of renal surgery for cortical neoplasms on lipid metabolism.

Authors:  Aditya Bagrodia; Ryan P Kopp; Reza Mehrazin; Hak J Lee; Michael A Liss; Ramzi Jabaji; Christopher J Kane; Robert W Wake; Anthony L Patterson; Jim Y Wan; Ithaar H Derweesh
Journal:  BJU Int       Date:  2014-07-15       Impact factor: 5.588

3.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

4.  Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009.

Authors:  Tetsuo Nishikawa; Masao Omura; Fumitoshi Satoh; Hirotaka Shibata; Katsutoshi Takahashi; Naohisa Tamura; Akiyo Tanabe
Journal:  Endocr J       Date:  2011-08-09       Impact factor: 2.349

Review 5.  Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Authors:  Adam Whaley-Connell; Megan S Johnson; James R Sowers
Journal:  Prog Cardiovasc Dis       Date:  2010 Mar-Apr       Impact factor: 8.194

Review 6.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.

Authors:  N D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2006-02

7.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

8.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

9.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

10.  Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.

Authors:  Takanobu Utsumi; Koji Kawamura; Takashi Imamoto; Hidekazu Nagano; Tomoaki Tanaka; Naoto Kamiya; Naoki Nihei; Yukio Naya; Hiroyoshi Suzuki; Tomohiko Ichikawa
Journal:  Int J Urol       Date:  2012-11-27       Impact factor: 3.369

View more
  2 in total

1.  Hypertension Cure Following Laparoscopic Adrenalectomy for Hyperaldosteronism is not Universal: Trends Over Two Decades.

Authors:  Takeshi Namekawa; Takanobu Utsumi; Tomoaki Tanaka; Mayuko Kaga; Hidekazu Nagano; Takashi Kono; Koji Kawamura; Naoto Kamiya; Takashi Imamoto; Hiroyoshi Suzuki; Tomohiko Ichikawa
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

2.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.